Healthcare / Medical DevicesThailand
$5.25
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-72.7M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.2B
P/E
8.0x
↓EV/EBITDA
8.2x
↓ROE
31.4%
↑Gross Margin
24.1%
↓Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.2%
FCF CAGR
—
FCF margin
-12.4%
FCF / Net income
-0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.02B · net income $305.6M · FCF $-251.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.02B | $2.02B | $1.71B | $1.69B | $1.23B |
| Net Income | $305.6M | $305.6M | $224.2M | $201.2M | $133.4M |
| EBITDA | $410.3M | $410.3M | $307.4M | $278.9M | $203.8M |
| EPS | — | — | 0.37 | 0.33 | 0.22 |
| Gross Margin | 24.1% | 24.1% | 21.7% | 19.7% | 20.5% |
| Operating Margin | 19.4% | 19.4% | 16.8% | 15.2% | 14.3% |
| Net Margin | 15.1% | 15.1% | 13.1% | 11.9% | 10.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.37 | 0.37 | 0.18 | 0.13 | 0.30 |
| Current Ratio | 2.28 | 2.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-251.6M | $-251.6M | $-72.7M | $638.5M | $218.4M |
| Returns | |||||
| ROE | 31.4% | 31.4% | 25.5% | 24.1% | 17.7% |
| Valuation | |||||
| P/E | 7.95 | 7.95 | 9.19 | 10.30 | 19.64 |
| EV/EBITDA | 8.20 | 8.20 | 5.93 | 5.59 | 12.88 |
| P/B | 3.24 | 3.24 | 2.35 | 2.49 | 3.50 |
| Growth & Yield | |||||
| Revenue Growth | 18.1% | 18.1% | 1.5% | 37.8% | — |
| EPS Growth | — | — | 12.1% | 50.0% | — |
| Dividend Yield | 10.7% | 10.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+52.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.37 → n/d
Residual
+41.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.